Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw

Polaris Capital's Q2 2026 investor letter highlights Lantheus Holdings (LNTH) as a top performer. The company's stock rose due to strong earnings, FDA approval of PYLARIFY TruVu, and a potential $7B takeover bid from Curium Pharma. LNTH's shares are up 92.62% over 52 weeks, closing at $100.28 on September 22, 2026, with a market cap of $6.55B.

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

Lantheus (LNTH) stockholders will vote on a $102.50 cash-plus-CVR sale to Curium, delisting LNTH from Nasdaq. Each share gets $102.50 cash plus a CVR for up to $12.00 more if milestones are met by 2031. The board recommends approval, requiring a majority vote. The deal, valued at $7.45 billion, needs stockholder and regulatory approvals.

In August 2026, Curium agreed to acquire Lantheus Holdings (LNTH) for up to $8 billion, consolidating the radiopharmaceutical sector and creating a global nuclear medicine group. The deal spans diagnostics and therapeutics across 70+ countries.